Navigation Links
Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
Date:6/2/2009

days 1 or 15. There were no statistically significant differences in the PK characteristics when HPN-100 was given fasting on day 1 or with a meal on day 8. Excretion of the main metabolite PAGN was similar between healthy adults and cirrhotic subjects. Urinary PAGN after the first dose on Day 1 ranged from 42-49% of the administered dose, and the mean total excretion of PAGN after the last dose in the study (day 15) ranged from 25,152 to 31,431 umol in the four treatment groups

There were no SAEs or AEs leading to withdrawal during the study. The most common system organ class was "investigations" (32 events in 18 subjects), and of these the most frequent individual AEs were increased body temperature, which was reported in 10 subjects (all from Child-Pugh groups A, B, and C), and decreased platelet count, which was reported in 4 subjects in Child-Pugh group A and 1 subject in the healthy volunteer group. There were no overall consistent patterns across all subject groups in changes in mean hematology, biochemistry, and coagulation variables.

"Hepatic encephalopathy (HE) is a significant clinical problem," said Brendan M. McGuire, M.D. Medical Director of Liver Transplantation at the University of Alabama. "I am encouraged by the phase I study results and look forward to further clinical studies."

About HPN-100

HPN-100 is an investigational product that is a pre-pro-drug of phenylacetic acid, the active moiety of BUPHENYL(R), the only therapy currently FDA-approved as adjunctive therapy for the chronic management of patients with the most prevalent urea cycle disorders: carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) and argininosuccinic acid synthetase (AS) deficiencies. HPN-100, which is dosed orally in liquid form, is under clinical investigation as providing a potential alternative pathway to the urea cycle for the disposal of waste nitrogen through the renal excretion
'/>"/>

SOURCE Hyperion Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
2. Hyperion Therapeutics Elects Lota Zoth to Board of Directors
3. Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
4. Prime Therapeutics Receives TIPPS Certification
5. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
6. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
7. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
8. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
9. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
10. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
11. Prime Therapeutics Announces URAC Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Woodloch Pines, an all-inclusive family ... by TripAdvisor as the number one best large hotel for ... the world for their annual Travelers’ Choice Awards. , ... The website is home to millions of unbiased and honest ...
(Date:1/22/2015)... 2015 Padre Murphy's and Owner Tom Boyle ... Pro Player Health Alliance (PPHA). The PPHA's passion for ... everyone, including NFL greats, treated for obstructive sleep apnea (OSA) ... supporting the cause in the valley. The most recent plans ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together by ... up to 30lbs in less than 12 weeks without traditional ... prompting an investigative review. , “Our Incredible Bulk review ... that allows the body to pack on a massive amount ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... reports from government health officials and the World Health Organization, ... She is the virus’ first human victim, in a year ... Mon Puthy, had been in close proximity with sick and ... 40 miles west of Phnom Penh. According to WHO spokeswoman ...
... resonance imaging (MRI) has been found to be insufficient, ... ,MRI has been adopted in England and Wales ... (NICE) as part of the recommended criteria for diagnosing ... evidence has not previously been systematically assessed. ...
... Organization (WHO) and UNICEF have announced a new formula ... is designed to minimize the occurrence of acute diarrhoeal ... agencies achieve the target of reducing child mortality by ... cause of child mortality and kills nearly 2 million ...
... caused by hereditary predisposition. Atopy is a determining factor ... allergens may help prevent adults from developing asthma.//,Journal of ... atopy and specific IgE to mites and molds important ... conducted by Maritta S. Jaakkola, MD, DSc, of the ...
... Minister of Bihar Mr. Nitish Kumar is all for a ... used to cultivate potato, tomato and green vegetables// at their ... resource centre for herbal farming. ,Nitish Kumar comes ... was a leading ayurvedic practitioner in his home district of ...
... With the announcement of the Food Standards Agency (FSA), that the ... day, and that the tinned foods// should clearly mention the amount ... issue has now picked up, with groups on either side. ... government of UK, has announced targets for reducing salt in a ...
Cached Medicine News:Health News:MRI Scan Insufficient For Diagnosing Multiple Sclerosis 2Health News:Salt & Its Intake Causes a Strong debate In UK 2
(Date:1/23/2015)... ORLANDO, Fla. and DUBLIN , ... of the agreement with KRS Global Biotechnology, Inc. for the ... will be compounded for shipment in the United ... 503B FDA approved Outsourcing Facility capable of compounding naltrexone tablets ...
(Date:1/23/2015)... available for sale, The Armor1 Ankle Roll Guard is a ... by cushioning the ankle from an inversion or "roll." ... of any shoe type and allows the user to ... against sprains. With customers in physical therapy, podiatry, and ...
(Date:1/23/2015)... 23, 2015   Leatt Corporation  (OTCQB: LEAT), a global ... all forms of sports, including extreme motor sports, and ... today that the UISP Lega Motociclismo Lombardia, an Italian ... to wear a neck brace during its racing competitions.  ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3
... Jan. 11, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: ... trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor ... "PARP inihibtors have been validated to show survival benefits ... repair or in combination with DNA damaging agents, and BMN ...
... Wis., Jan. 11, 2011 RF Technologies®, a ... and healthcare security solutions, has announced a distributor ... leading provider of medical equipment management and service ... on November 1, UHS will offer the RF ...
Cached Medicine Technology:BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 2BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 3RF Technologies® Announces Distributor Agreement With Universal Hospital Services 2
... Endoscopic CycloPhotocoagulation (ECP) is a surgical approach ... and visualized laser application. The ciliary body ... the surgeon, from the anterior or posterior ... The target tissues are easily and accurately ...
... of German Craftsmanship have produced ... the world. Ocutek® now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... Centuries of German Craftsmanship have ... in the world. Ocutek® now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
... Centuries of German Craftsmanship have ... in the world. Ocutek® now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
Medicine Products: